Project Grant R01AR085823
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846), awarded a $726,898 Project Grant to Weill Medical College of Cornell University. The grant, awarded on August 1, 2025, will support a research project titled "Personalized Immunomonitoring to Understand Juvenile Dermatomyositis" with Principal Investigators Pascual, V. and Wilson, P. The project aims to...
- This Project Grant award, totaling $176,148.00 and effective from April 1, 2025 to March 31, 2030, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The funding supports a research project led by Dr. Maxime Kinet at the University of California, San Francisco (UCSF) that aims to elucidate the mechanisms by which PI16-expressing fibroblasts, a...
- This federal Project Grant award, valued at $1,901,310.00 and provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project aims to investigate how skin inflammation drives the development of psoriatic arthritis, a condition that affects up to one-third of individuals with psoriasis. The project will use a novel mouse model to study the...
- This federal Project Grant award for $243,950.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a series of research aims to develop prognostic models for predicting the long-term course of atopic dermatitis (persistent disease and comorbidities) in diverse global settings, including cohorts from Uganda, Ecuador, and the United Kingdom....
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define and treat genetic abnormalities in overlapping rashes of psoriasis and atopic dermatitis (termed "PSO-AD"). The $628,968 award to the University of California, San Francisco will leverage innovative biomarker techniques, including spatial transcriptomics and...
- This $169,560.00 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research focused on understanding the role of the endogenous opioid system in regulating inflammation, itch, and pain associated with inflammatory skin diseases. The primary recipient, The Regents of the University of California, San Francisco (UCSF), will conduct this research...
- This federal Project Grant award of $528,558.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The goal of the research project is to study the immune system mechanisms underlying treatment resistance and paradoxical inflammatory side effects in patients with atopic dermatitis who receive the antibody therapy dupilumab. The research will...
- This Project Grant award of $147,400.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the mechanisms by which antigen non-related CD4+ T cells contribute to the pathogenesis of skin fibrosis in systemic sclerosis (scleroderma) and sclerodermoid graft-versus-host disease. The project, conducted by Yale University, will use mouse models to...
- This federal Project Grant award of $102,341 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research at Stanford University to characterize the role of RNA-binding protein assemblies in epidermal homeostasis. The research aims to better understand how these protein complexes regulate keratinocyte proliferation and differentiation, which is critical for...
This $366,639 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) supports research to understand the mechanisms driving poor outcomes in women with dermatomyositis, a rare autoimmune disease. The key objectives are to: 1) Establish the Southern California Dermatomyositis Disease Network, a patient-centered registry to recruit diverse patients with dermatomyositis and associated interstitial lung disease, and 2) Investigate whether microvascular disease drives progression of myositis-associated interstitial lung disease using novel imaging and histological approaches. The research aims to identify biomarkers and therapeutic targets to improve outcomes for this underserved patient population. The award, effective Sep 5, 2025, has an ultimate completion date of Aug 31, 2029 and is being performed by the University of California, Los Angeles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $366.6k | 9/4/25 |